Synthetic isothiocyanate indole-3-ethyl isothiocyanate (homoITC) enhances sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to cisplatin

Neoplasma

Volumn 57, Issue 5, 2010, Pages 473-481

  Stehlik, P ^a   Paulikova, H ^b   Hunakova, L ^a  

^a Cancer Research Institute   (Slovakia)

^b SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

Author keywords

Apoptosis; Cisplatin; Growth inhibition; Isothiocyanate; Ovarian carcinoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; CISPLATIN; INDOLE 3 ETHYL ISOTHIOCYANATE; ISOTHIOCYANIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INDOLE-3-ETHYL ISOTHIOCYANATE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CARCINOMA; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; DRUG RESISTANCE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; ISOTHIOCYANATES; OVARIAN NEOPLASMS;

EID: 79851511374     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_05_473     Document Type: Article

References (39)

1. ORENDAS P, KASSAYOVA M, KAJO K et al. Celecoxib and melatonin in prevention of female rat mammary carcinogenesis. Neoplasma 2009; 56: 252-258. doi:10.4149/ neo_2009_03_252
2. GERHAUSER C, YOU M, LIU JF et al. Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drug-metabolizing enzymes. Cancer Research 1997; 57: 272-278.
3. PAPPA G, BARTSCH H, GERHAUSER C. Biphasic modulation of cell proliferation by sulforaphane at physiologically relevant exposure times in a human colon cancer cell line. Mol Nutr Food Res 2007; 51: 977-984. doi:10.1002/mnfr.200700115
4. PAPPA G, STRATHMANN J, LOWINGER M et al. Quantitative combination effects between sulforaphane and 3,3'-diindolylmethane on proliferation of human colon cancer cells in vitro. Carcinogenesis 2007; 28: 1471-1477. doi:10.1093/carcin/bgm044
5. KUBATKA P, SADLONOVA V, KAJO K et al. Preventive effects of letrozole in the model of premenopausal mammary carcinogenesis. Neoplasma 2008; 55: 42-46.
6. BOJKOVA B, ORENDAS P, GARAJOVA M et al. Metformin in chemically-induced mammary carcinogenesis in rats. Neoplasma 2009; 56: 269-274. doi:10.4149/neo_2009_03_269
7. MEZENCEV R, KUTSCHY P, SALAYOVA A et al. The design, synthesis and anticancer activity of new nitrogen mustard derivatives of natural indole phytoalexin 1-methoxyspirobrassinol. Neoplasma 2009; 56: 321-330. doi:10.4149/neo_2009_04_321
8. DURAJ J, HUNAKOVA L, BODO J et al. Administration of isothiocyanate (E-4IB) and cisplatin leads to altered signalling and lysosomal export in human ovarian carcinoma sensitiveand cisplatin-resistant cells. Neoplasma 2009; 56: 208-214. doi:10.4149/neo_2009_03_208
9. PAULIKOVA H, KADLECIKOVA E, SUCHANOVA M et al. Cytotoxicity of copper(II) complexes of N-salicylidene-L-glutamate: modulation by ascorbic acid. Neoplasma 2008; 55: 338-344.
10. SUFLIARSKY J, CHOVANEC J, SVETLOVSKA D et al. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer. Neoplasma 2009; 56: 291-297. doi:10.4149/ neo_2009_04_291
11. BODO J, CHOVANCOVA J, HUNAKOVA L et al. Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate. Neoplasma 2005; 52: 510-516.
12. HORAKOVA K., DROBNICA L, NEMEC P. et al. Cytotoxic and cancerostatic activity of isothiocyanates and related compounds. I. Activity of some naturally occuring isothiocyanates and their synthetic analogues on HeLa cells. Neoplasma 1968; 15: 169-175.
13. SHUKLA S, GUPTA S. Dietary agents in the chemoprevention of prostate cancer. Nutr Cancer 2005; 53: 18-32. doi:10.1207/ s15327914nc5301_3
14. MEHTA RG, LIU JF, CONSTANTINOU A et al. Cancer Chemopreventive Activity of Brassinin, A Phytoalexin from Cabbage. Carcinogenesis 1995; 16: 399-404. doi:10.1093/ carcin/16.2.399
15. BANERJEE T, DUHADAWAY JB, GASPARI P et al. A key in vivo antitumor mechanism of action of natural productbased brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 2008; 27: 2851-2857. doi:10.1038/sj.onc.1210939
16. KUTSCHY P, SALAYOVA A, CURILLOVA Z et al. 2-(substituted phenyl)amino analogs of 1-methoxyspirobrassinol methyl ether: synthesis and anticancer activity. Bioorg Med Chem 2009; 17: 3698-3712. doi:10.1016/j.bmc.2009.03.064
17. HAYES JD, KELLEHER MO, EGGLESTON IM. The cancer chemopreventive actions of phytochemicals derived from glucosinolates. Eur J Nutr 2008; 47 Suppl 2: 73-88. doi:10.1007/s00394-008-2009-8
18. SINGH RK, LANGE TS, KIM K et al. Effect of indole ethyl isothiocyanates on proliferation, apoptosis, and MAPK signaling in neuroblastoma cell lines. Bioorg Med Chem Lett 2007; 17: 5846-5852. doi:10.1016/j.bmcl.2007.08.032
19. SINGH RK, LANGE TS, KIM KK et al. Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cellcycle regression in ovarian cancer cells. Br J Cancer 2008; 99: 1823-1831. doi:10.1038/sj.bjc.6604778
20. BRARD L, SINGH RK, KIM KK et al. Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells. Drug Des Devel Ther 2009; 2: 61-69.
21. ZHANG Y. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. Carcinogenesis 2000; 21: 1175-1182. doi:10.1093/carcin/21.6.1175
22. TELANG U, Ji Y, MORRIS ME. ABC transporters and isothiocyanates: potential for pharmacokinetic diet-drug interactions. Biopharm Drug Dispos 2009; 30: 335-344. doi:10.1002/bdd.668
23. AGARWAL R, KAYE SB. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-516. doi:10.1038/nrc1123
24. WERNYJ RP, MORIN PJ. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Update 2004; 7: 227-232. doi:10.1016/j.drup.2004.08.002
25. PARK S, HAYES BL, MARANKAN F et al. Regioselective covalent modification of hemoglobin in search of antisickling agents. J Med Chem 2003; 46: 936-953. doi:10.1021/jm020361k
26. BARTKOWIAK D, HOGNER S, BAUST H et al. Comparative analysis of apoptosis in HL60 detected by annexin-V and fluorescein-diacetate. Cytometry 1999; 37: 191-196. doi:10.1002/(SICI)1097-0320(19991101)37:3<191:: AID-CYTO5>3.0.CO;2-U
27. MOSMANN T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63. doi:10.1016/ 0022-1759(83)90303-4
28. CHOU TC, MOTZER RJ, TONG Y et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-1524. doi:10.1093/jnci/86.20.1517
29. PEREZ RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34: 1535-1542. doi:10.1016/ S0959-8049(98)00227-5
30. HELLEMAN J, BURGER H, HAMELERS IH et al. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter. Cancer Biol Ther 2006; 5: 943-949.
31. BODO J, HUNAKOVA L, KVASNICKA P et al. Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations. Br J Cancer 2006; 95: 1348-1353. doi:10.1038/sj.bjc.6603434
32. CHUANG LT, MOQATTASH ST, GRETZ HF et al. Sulforaphane induces growth arrest and apoptosis in human ovarian cancer cells. Acta Obstet Gynecol Scand 2007; 1-6.
33. KANG L, WANG ZY. Breast Cancer Cell Growth Inhibition by Phenethyl Isothiocyanate is Associated with Downregulation of Estrogen Receptor-alpha36. J Cell Mol Med 2009;
34. ADSULE S, BANERJEE S, AHMED F et al. Hybrid anticancer agents: isothiocyanate-progesterone conjugates as chemotherapeutic agents and insights into their cytotoxicities. Bioorg Med Chem Lett 2010; 20: 1247-1251. doi:10.1016/ j.bmcl.2009.11.128
35. HUNAKOVA L, SEDLAKOVA O, CHOLUJOVA D et al. Modulation of markers associated with aggressive phenotype in MDA-MB-231 breast carcinoma cells by sulforaphane. Neoplasma 2009; 56: 548-556. doi:10.4149/neo_2009_06_548
36. WANG XH, CAVELL BE, SYED ALWI SS et al. Inhibition of hypoxia inducible factor by phenethyl isothiocyanate. Biochem Pharmacol 2009; 78: 261-272. doi:10.1016/ j.bcp.2009.04.010
37. PIEKARZ RL, BATES SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009; 15: 3918-3926. doi:10.1158/1078-0432.CCR-08-2788
38. ZHANG YS, TALALAY P. Mechanism of differential potencies of isothiocyanates as inducers of anticarcinogenic phase 2 enzymes. Cancer Res 1998; 58: 4632-4639.
39. JANSEN BA, BROUWER J, REEDIJK J. Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. J Inorg Biochem 2002; 89: 197-202. doi:10.1016/S0162-0134(02)00381-1